Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
Both of these biotech stocks could be appealing to income investors.
Amgen and Gilead Sciences are two notable biotech stocks that offer attractive dividends, despite most biotech companies not being able to afford this practice. Both companies have distinct strategies for navigating future drug development. To determine which dividend-paying biotech stock is the better buy for long-term investors, it is crucial to compare various factors.
Yield is an essential aspect to consider when comparing dividend stocks. Amgen boasts a higher forward dividend yield at 2.2%, whereas Gilead Sciences' yield is slightly below 2.1%. Additionally, examining the dividend payout ratios provides insight into a company's financial health. Gilead Sciences has a lower payout ratio of 43.5%, compared to Amgen's 60.9%, indicating that Gilead is more conservatively distributing its earnings to shareholders.
Valuation also plays a significant role in evaluating dividend stocks. Gilead Sciences is currently trading at a lower forward earnings multiple of 15.6 times compared to Amgen's 16.7. However, determining which company is better positioned to continue paying dividends in the years to come requires a deeper analysis of their current product lineups, competitive dynamics, and pipeline programs.
Amgen's current lineup appears slightly stronger than Gilead's, with a 9% year-over-year increase in product sales and revenue from 17 drugs on track to become blockbusters. In contrast, Gilead Sciences claims to have a more robust pipeline with 53 clinical-stage programs, 15 of which are in Phase 3 clinical studies. Yet, Amgen's pipeline consists of 44 programs, with 29 in late-stage development.
Ultimately, the decision between Amgen and Gilead Sciences depends on an investor's priorities. Income investors focused on yield and growth may prefer Amgen, given its higher yield and potentially superior product lineup and pipeline. Meanwhile, investors who prioritize safety and value might lean towards Gilead Sciences, which offers a lower payout ratio.
However, for many investors, owning both stocks could be the best strategy, as they both provide higher dividend yields than the S&P 500 and have more attractive valuations.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
